Abstract
摘要
相似文献
1
Pancreatic cancer.
Clin Evid. 2004 Jun(11):626-32.
2
Chemotherapy for pancreatic cancer.
N Engl J Med. 2004 Jun 24;350(26):2713-5; author reply 2713-5.
3
Chemotherapy for pancreatic cancer.
N Engl J Med. 2004 Jun 24;350(26):2713-5; author reply 2713-5. doi: 10.1056/NEJM200406243502617.
4
Adjuvant therapy for pancreatic and periampullary cancer.
Trop Gastroenterol. 2000 Jul-Sep;21(3):129-30.
5
[Multimodality therapy of operable pancreatic cancer].
Strahlenther Onkol. 1999 Aug;175(8):413-4.
6
A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
Jpn J Clin Oncol. 2006 Mar;36(3):159-65. doi: 10.1093/jjco/hyi234. Epub 2006 Feb 20.
7
On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer.
Ann Surg. 2006 Aug;244(2):332-3; author reply 333. doi: 10.1097/01.sla.0000229980.81505.44.
8
Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study.
Am J Clin Oncol. 2008 Feb;31(1):71-8. doi: 10.1097/COC.0b013e31807a328c.
9
A challenge to the therapeutic nihilism of ESPAC-1.
Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):965-6. doi: 10.1016/j.ijrobp.2004.11.018.
10
Feasibility and efficacy of combination therapy with preoperative and postoperative chemoradiation, extended pancreatectomy, and postoperative liver perfusion chemotherapy for locally advanced cancers of the pancreatic head.
Ann Surg Oncol. 2005 Aug;12(8):629-36. doi: 10.1245/ASO.2005.05.028. Epub 2005 Jun 22.
Zotero 插件